In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC ® small molecules toward key clinical milestones,” said Pratik Shah, Ph.D., ...

Eisai & Biogen announce update on regulatory review of MAA for lecanemab to treat early Alzheimer’s disease by European Commission: Tokyo Wednesday, April 16, 2025, 11:00 Hrs [I ...

City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced additions to its executive team and board of directors ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common ...

Blackstone and BioMed Realty have proposed turning a five-story office building near MIT into life sciences labs.

After getting a green light from the European Commission, Biogen’s Skyclarys is the first ... families,” said Sylvia Boesch of Medical University Innsbruck in Austria, who was principal ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...